Anti-hypertensive drug by Mankind launched

A New Delhi based pharmaceutical company called Mankind Pharma has launched an anti-hypertensive drug Zolahart (Azilsartan) at a very affordable price of Rs 7.5 per tablet.

The Goan NetworkPublished May 17, 2017, 6:33 PM IST

SHARE ON

the goan I network

Panaji

Speaking on the development, R C Juneja, chairman and founder, Mankind Group, said “We endeavour to bring the latest innovative therapies with assured quality that address primary healthcare challenge in India “ world class quality at an affordable price. It is with this thought that we decided to launch Zolahart (Azilsartan), the latest anti-hypertensive drug at the most affordable price of Rs 7.50/Tab, which is 51% less than other competitors.”

In a press note, Mankind Pharma said, “Azilsartan offers potent and

persistent 24 hours blood pressure control. It is proven to be safe for hypertensive patients with comorbid conditions like diabetes or chronic kidney disease”

SHARE ON

Vedanta’s FY’17 profit more than doubles

The diversified natural resources company, Vedanta, posted its financial results for the year ending March 2017 and it reported that its net profit stood at Rs 7,323 crores, which was 158% more than previous year’s profit of Rs 2,839 crores.

The Goan Network

Published May 17, 2017, 6:33 PM IST

SHARE ON

the goan I networkPANAJI Meanwhile, the company also reported 12% growth in sales which increased from Rs 63,920 crores in FY 2016 to Rs 71,721 crores in FY 2017. EBITDA (earnings before interest, tax, depreciation and amortization) jumped by 41% to reach Rs 21,437 crores in FY 2017. Vedanta is into iron ore mining in Goa and apart from that it is into mining of a number of minerals around the world. Speaking about the company’s performance, Tom…

Anti-hypertensive drug by Mankind launched

Vedanta’s FY’17 profit more than doubles

Keep Reading — More from THE GOAN SPECIAL

SPOTLIGHT | Crisis in RGP opens new questions for Opposition

Busy with money or actually making progress?

Aid Indians first, then world